Pharming Net Debt To E B I T D A from 2010 to 2025
| PHAR Stock | USD 8.65 0.13 1.48% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter 10.01 | Current Value 10.51 | Quarterly Volatility 5.4189991 |
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 16.3 M, Interest Expense of 6.4 M or Selling And Marketing Expenses of 120.4 M, as well as many indicators such as Price To Sales Ratio of 4.16, Dividend Yield of 0.0 or PTB Ratio of 3.92. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
Pharming | Net Debt To E B I T D A |
Latest Pharming Group's Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Pharming Group NV over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Pharming Group's Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Pharming Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | 1.15 | |
| Geometric Mean | 0.99 | |
| Coefficient Of Variation | 471.37 | |
| Mean Deviation | 3.55 | |
| Median | 0.02 | |
| Standard Deviation | 5.42 | |
| Sample Variance | 29.37 | |
| Range | 21.7792 | |
| R-Value | 0.57 | |
| Mean Square Error | 21.16 | |
| R-Squared | 0.33 | |
| Significance | 0.02 | |
| Slope | 0.65 | |
| Total Sum of Squares | 440.48 |
Pharming Net Debt To E B I T D A History
About Pharming Group Financial Statements
Pharming Group shareholders use historical fundamental indicators, such as Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | 10.01 | 10.51 |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.